Novavax Income Statement Analysis

Revenue, earnings, and profit margins in billions USD

Scroll to see more
Novavax, Inc. income statement - Annual data in billions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.680.981.981.150.020.010.03
Cost of Revenue0.201.042.072.530.750.000.00
Gross Profit0.48-0.05-0.09-1.390.020.010.00
Operating Expenses
Research & Development0.390.040.072.530.750.110.17
Selling, General & Administrative0.340.460.490.300.150.030.03
Operating Expenses0.730.500.560.300.890.150.21
Operating Income-0.25-0.55-0.64-1.69-0.42-0.12-0.17
Other Income/Expense
Interest Income0.000.000.000.000.000.000.00
Interest Expense0.02-0.01-0.02-0.02-0.020.000.01
Other Income/Expense0.070.030.010.00-0.01-0.010.00
Income
Income Before Tax-0.18-0.54-0.65-1.71-0.42-0.14-0.18
Income Tax Expense0.010.000.000.030.000.000.00
Net Income-0.19-0.55-0.66-1.74-0.42-0.13-0.18
Net Income - Continuous Operations-0.19-0.55-0.66-1.740.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-0.11-0.51-0.62-1.67-0.40-0.11-0.16
EBIT-0.17-0.55-0.64-1.69-0.40-0.12-0.17
Depreciation & Amortization0.050.040.030.010.000.010.00
Earnings Per Share
Basic EPS-1.00-5.00-8.00-23.00-7.00-6.00-10.00
Diluted EPS-1.00-5.00-8.00-23.00-7.00-6.00-10.00
Basic Shares Outstanding0.150.100.080.070.060.020.02
Diluted Shares Outstanding0.150.100.080.070.060.020.02